Medical and surgical interventions for hearing loss associated with congenital cytomegalovirus: A systematic review

Otolaryngology - Head and Neck Surgery

Volumn 144, Issue 5, 2011, Pages 662-675

  Shin, Jennifer J ^a,b   Keamy Jr , Donald G ^a   Steinberg, Evan A ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b LOS ANGELES MEDICAL CENTER   (United States)

Author keywords

Antiviral; Cytomegalovirus; Hearing loss; Systematic review

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; VALGANCICLOVIR;

ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; EMBASE; HEARING LOSS; HUMAN; IMPLANTATION; MEDLINE; NEUTROPENIA; PERCEPTION DEAFNESS; REVIEW; SYSTEMATIC REVIEW; VIROLOGY;

CYTOMEGALOVIRUS INFECTIONS; HEARING LOSS; HUMANS;

EID: 80051709682     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599811399241     Document Type: Review

References (28)

1. Mehra S, Eavey RD, Keamy DG Jr. The epidemiology of hearing impairment in the United States: newborns, children, and adolescents. Otolaryngol Head Neck Surg. 2009;140:461-472.
2. Kenna MA. Medical management of childhood hearing loss. Pediatr Ann. 2004;33:822-832. (Pubitemid 39648092)
3. Schroeder L, Petrou S, Kennedy C, et al. The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics. 2006;117:1101-1112. (Pubitemid 46071501)
4. Nassetta L, Kimberlin D, Whitley R. Treatment of congenital cytomegalovirus infection: implications for future therapeutic strategies. J Antimicrob Chemother. 2009;63:862-867.
5. Pass RF. Congenital cytomegalovirus infection and hearing loss. Herpes. 2005;12:50-55. (Pubitemid 41512784)
6. Kimberlin DW, Lin CY, Sanchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16-25. (Pubitemid 36928564)
7. Lackner A, Acham A, Alborno T, et al. Effect on hearing of ganciclovir therapy for asymptomatic congenital cytomegalovirus infection: four to 10 year follow up. J Laryngol Otol. 2009;123:391-396.
8. Whitley RJ, Cloud G, Gruber W, et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1997;175:1080-1086. (Pubitemid 27176494)
9. Tanaka-Kitajima N, Sugaya N, Futatani T, et al. Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J. 2005;24:782-785. (Pubitemid 41324886)
10. Weng YH, Chu SM, Lien RI, et al. Clinical experience with ganciclovir and anti-cytomegalovirus immunoglobulin treatment for a severe case of congenital cytomegalovirus infection. Chang Gung Med J. 2003;26:128-132.
11. Rojo P, Ramos JT. Ganciclovir treatment of children with congenital cytomegalovirus infection. Pediatr Infect Dis J. 2004;23:88-89. (Pubitemid 38176780)
12. Amir J, Wolf DG, Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr. 2010;169:1061-1067.
13. Michaels MG, Greenberg DP, Sabo DL, et al. Treatment of children with congenital cytomegalovirus infection with ganciclovir. Pediatr Infect Dis J. 2003;22:504-509.
14. Yilmaz Ciftdogan D, Vardar F. Effect on hearing of oral valganciclovir for asymptomatic congenital cytomegalovirus infection. J Trop Pediatr. Epub ahead of print, June 24, 2010.
15. Meine Jansen CF, Toet MC, Rademaker CM, et al. Treatment of symptomatic congenital cytomegalovirus infection with valganciclovir. J Perinat Med. 2005;33:364-366. (Pubitemid 41205874)
16. Lombardi G, Garofoli F, Villani P, et al. Oral valganciclovir treatment in newborns with symptomatic congenital cytomegalovirus infection. Eur J Clin Microbiol Infect Dis. 2009;28:1465-1470.
17. Hilgendorff A, Daiminger A, Dangel V, et al. Oral valganciclovir treatment in a CMV congenital infected infant with sensorineural hearing loss (SNHL) first detected at 4 months of age. Klin Padiatr. 2009;221:448-449.
18. Iwasaki S, Nakanishi H, Misawa K, et al. Cochlear implant in children with asymptomatic congenital cytomegalovirus infection. Audiol Neurootol. 2009;14:146-152.
19. Fukushima K, Kawasaki A, Nagayasu R, et al. Developmental dysgraphia with profound hearing impairment: intervention by auditory methods enabled by cochlear implant. Auris Nasus Larynx. 2008;35:250-254.
20. Yoshida H, Kanda Y, Takahashi H, et al. Cochlear implantation in children with congenital cytomegalovirus infection. Otol Neurotol. 2009;30:725-730.
21. Ramirez Inscoe JM, Nikolopoulos TP. Cochlear implantation in children deafened by cytomegalovirus: speech perception and speech intelligibility outcomes. Otol Neurotol. 2004;25:479-482. (Pubitemid 39079766)
22. Pyman B, Blamey P, Lacy P, et al. The development of speech perception in children using cochlear implants: effects of etiologic factors and delayed milestones. Am J Otol. 2000;21:57-61. (Pubitemid 30036498)
23. Ciorba A, Bovo R, Trevisi P, et al. Rehabilitation and outcome of severe profound deafness in a group of 16 infants affected by congenital cytomegalovirus infection. Eur Arch Otorhinolaryngol. 2009;266:1539-1546.
24. Lee DJ, Lustig L, Sampson M, et al. Effects of cytomegalovirus (CMV) related deafness on pediatric cochlear implant outcomes. Otolaryngol Head Neck Surg. 2005;133:900-905. (Pubitemid 41797243)
25. Kimberlin DW, Acosta EP, Sanchez PJ, et al. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197:836-845. (Pubitemid 351417006)
26. Stagno S, Pass RF, Dworsky ME, et al. Congenital and perinatal cytomegalovirus infections. Semin Perinatol. 1983;7:31-42.
27. Year 2007 position statement: principles and guidelines for early hearing detection and intervention programs. Pediatrics. 2007;120:898-921.
28. Lombardi G, Garofoli F, Stronati M. Congenital cytomegalovirus infection: treatment, sequelae and follow-up. J Matern Fetal Neonatal Med. 2010;3(suppl 3):45-48.